Open access
Oct 2026
Targeting CD28 on T lineage malignancies with chimeric antigen receptor T cells
Currently, no immunotherapy is approved for T cell acute lymphoblastic leukemia (T‑ALL). High initial response rates to CD7‑directed chimeric antigen receptor (CAR) T cells are limited by profound T cell aplasia and CD7‑negative immune escape, underscoring the need for alternative targets. Here, we show that CD28 is ov...
Semjon Willier, Julian Färber, Theodora Ispyrlidou et al.
· Nature Communications · 0 citations